Table 1Baseline characteristics according to types of statin
Characteristic |
Atorvastatin |
Rosuvastatin |
Pitavastatin 2 mg |
Pravastatin 40 mg |
10 mg |
20 mg |
5 mg |
10 mg |
Male sex |
60 (35.0) |
58 (34.5) |
60 (50.0) |
60 (48.3) |
57 (49.1) |
60 (50.0) |
Age, yr |
67±8 |
65±9 |
59±10 |
61±11 |
64±9 |
66±10 |
BMI, kg/m2
|
25.3±2.7 |
24.6±3.5 |
24.8±3.1 |
26.2±3.6 |
24.9±3.1 |
24.3±2.4 |
DM duration, yr |
12±8 |
10±7 |
9±7 |
12±9 |
11±8 |
12±8 |
HbA1c, %a
|
7.0 (1.2) |
8.0 (1.2) |
7.0 (1.1) |
7.7 (1.2) |
7.3 (1.2) |
7.0 (1.2) |
AST, mg/dLa
|
23.6 (1.5) |
21.9 (1.9) |
23.7 (1.5) |
21.9 (1.6) |
22.2 (1.7) |
21.8 (1.7) |
ALT, mg/dLa
|
22.5 (1.9) |
23.1 (1.6) |
23.1 (1.6) |
21.9 (1.6) |
22.2 (1.7) |
21.8 (1.7) |
Creatinine, mg/dLa
|
0.9 (1.3) |
0.9 (1.5) |
0.9 (1.2) |
0.8 (1.2) |
1.0 (1.2) |
0.9 (1.2) |
Hypertension |
27 (45.0) |
24 (41.4) |
17 (28.3) |
32 (53.3) |
26 (45.6) |
22 (36.7) |
Ever smoker |
15 (25.0) |
20 (33.3) |
16 (26.7) |
16 (26.7) |
17 (29.8) |
18 (30.0) |
Current alcohol intake |
8 (26.7) |
9 (26.5) |
15 (37.5) |
10 (30.3) |
6 (18.8) |
12 (34.3) |
10-Year ASCVD risk, %a
|
23 (26) |
19 (23) |
12 (16) |
15 (25) |
20 (21) |
27 (29) |
LDL-C baseline, mg/dL |
134.0±28.2 |
142.3±33.0 |
136.3±31.0 |
143.8±35.6 |
121.6±20.8 |
130.1±18.5 |
HDL-C baseline, mg/dL |
43.0 (16.8) |
40.0 (14.5) |
45.9 (15.0) |
44.0 (11.0) |
44.0 (11.5) |
43.0 (12.8) |
TG baseline, mg/dLa
|
130.5 (77.5) |
166.5 (107.0) |
135.5 (104.3) |
141.5 (86.3) |
125.0 (70.0) |
128.5 (75.0) |
Table 2The change of LDL-C levels after 6 months of statin treatment
Variable |
Atorvastatin |
Rosuvastatin |
Pitavastatin 2 mg |
Pravastatin 40 mg |
Total |
10 mg |
20 mg |
5 mg |
10 mg |
LDL-C baseline, mg/dL |
134.0±28.2 |
142.3±33.0 |
136.3±31.0 |
143.8±35.6 |
121.6±20.8 |
130.1±18.5 |
134.8±29.4 |
LDL-C after 6 months, mg/dL |
84.0±26.9a
|
75.4±18.3a
|
71.7±17.3a
|
69.4±24.0a
|
74.7±16.0a
|
79.0±20.9a
|
75.9±21.3a
|
LDL-C change after 6 months, mg/dL |
−61.5 (−77.0 to −37.8) |
−67.0 (−94.0 to −37.0) |
−73.0 (−90.5 to −50.0) |
−84.0 (−97.5 to −65.0) |
−51.0 (−64.0 to −35.0) |
−56.0 (−67.0 to −38.0) |
−63.0 (−83.0 to −40.0) |
LDL-C change after 6 months, % |
−44.1 (−52.6 to −36.6) |
−48.2 (−56.6 to −35.5) |
−51.6 (−59.5 to −37.3) |
−56.0 (−62.5 to −45.2) |
−41.7 (−49.1 to −29.2) |
−42.4 (−50.7 to −31.0) |
−47.4 (−56.6 to −34.1) |
30%−50% LDL-C decreased |
28 (46.7) |
18 (31.0) |
22 (36.7) |
10 (16.7) |
29 (50.9) |
29 (48.3) |
136 (38.3) |
LDL-C decreased >50% |
20 (33.3) |
28 (48.3) |
33 (55.0) |
42 (70.0) |
11 (19.3) |
16 (26.7) |
150 (42.3) |
LDL-C <100 mg/dL |
49 (81.7) |
54 (93.1) |
57 (95.0) |
57 (95.0) |
55 (96.5) |
55 (91.7) |
327 (92.1) |
Table 3The change of HDL-C, TG, TC levels, and 10-year ASCVD risks after 6 months of statin treatment
Variable |
Atorvastatin |
Rosuvastatin |
Pitavastatin 2 mg |
Pravastatin 40 mg |
Total |
10 mg |
20 mg |
5 mg |
10 mg |
HDL-C baseline, mg/dL |
42.5 (35.0 to 50.0) |
39.0 (35.0 to 49.0) |
45.0 (38.5 to 53.5) |
43.5 (38.5 to 51.5) |
44.0 (38.0 to 48.0) |
43.0 (37.0 to 50.0) |
43.0 (37.0 to 50.0) |
HDL-C after 6 months, mg/dL |
42.5 (35.0 to 50.0) |
40.0 (35.5 to 46.5) |
45.0 (38.0 to 53.0) |
44.5 (38.0 to 48.5) |
45.0 (39.0 to 51.0) |
45.0 (39.0 to 55.0) |
43.0 (37.0 to 51.0) |
HDL-C change after 6 months, % |
0.0 (−7.7 to 14.3) |
−2.8 (−10.6 to 8.5) |
−2.1 (−11.1 to 7.1) |
2.9 (−8.7 to 12.7) |
−1.6 (−10.4 to 6.4) |
2.6 (0.0 to 13.6) |
0.0 (−8.8 to 10.4) |
TG baseline, mg/dLa
|
134.0 (93.0 to 177.0) |
166.0 (112.0 to 212.5) |
130.0 (101.0 to 192.5) |
137.5 (100.5 to 188.5) |
126.0 (95.0 to 169.0) |
126.0 (107.0 to 185.0) |
134.0 (100.0 to 189.0) |
TG after 6 months, mg/dLa
|
113.0 (86.0 to 155.0) |
126.0 (82.0 to 158.5)b
|
120.0 (89.5 to 179.5) |
128.0 (91.5 to 162.5)b
|
104.0 (80.0 to 142.0) |
111.0 (79.0 to 158.0) |
120.0 (83.0 to 159.0) |
TG change after 6 months, % |
−15.5 (−31.1 to 7.5) |
−22.3 (−40.1 to 10.7) |
−8.9 (−32.9 to 23.6) |
−12.6 (−29.1 to 9.0) |
−15.9 (−33.2 to 13.6) |
−9.4 (−30.2 to 9.1) |
−12.9 (−34.2 to 11.0) |
TC baseline, mg/dL |
202.4±31.8 |
213.9±33.7 |
203.1±34.3 |
207.9±45.0 |
182.6±31.7 |
197.3±25.6 |
201.3±35.3 |
TC after 6 months, mg/dL |
153.2±32.4b
|
139.7±21.2b
|
140.3±20.2b
|
136.0±25.5b
|
136.9±28.9b
|
147.8±25.4b
|
142.4±26.4b
|
TC change after 6 months, % |
−24.7±13.4 |
−33.1±13.2 |
−29.9±12.7 |
−25.7±6.1 |
−15.2±7.9 |
−24.8±10.1 |
−25.6±14.2 |
LDL-C/HDL-C ratio baseline |
3.3±1.1 |
3.5±1.1 |
3.2±1.1 |
3.3±1.2 |
2.8±0.8 |
3.1±0.8 |
3.2±1.0 |
LDL-C/HDL-C ratio after 6 months, % |
2.0±0.8b
|
1.9±0.5b
|
1.7±0.6b
|
1.6±0.6b
|
1.8±0.6b
|
1.8±0.5b
|
1.8±0.6b
|
10-Year ASCVD baseline, % |
26.7±16.7 |
22.1±15.1 |
15.7±12.9 |
20.7±17.6 |
24.2±15.2 |
28.4±16.3 |
22.9±16.1 |
10-Year ASCVD after 6 months, % |
21.9±15.7b
|
17.0±13.8b
|
11.6±11.4b
|
16.3±15.8b
|
19.8±14.2b
|
23.8±15.6b
|
18.4±14.9b
|